📌 Key Takeaways
- Topic: Silica vs Silicon: What Is the Difference?
- Keywords: silica for UV adhesive
- Published: 2026-11-20 07:21:40
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
Spherical Silica Market 2026: Semiconductor Packaging Demand and Growth Outlook
- Silica in Makeup Powder: Benefits for Oil Absorption and Blurring Effects
- What Is Nano Silica? Particle Size, Properties, Production and Applications
- 103. Ibrahim A.H., Smått J.-H., Govardhanam N.P., Ibrahim H.M., Ismael H.R., Afouna M.I., Samy A.M., Rosenholm J.M. Formulation and optimization of drug-loaded mesoporous silica nanoparticle-based tablets to boost the dissolution rate of the poorly water-soluble drug silymarin. Eur. J. Pharm. Sci. 2020;142:105103. doi: 10.1016/j.ejps.2019.105103. [ DOI ] [ PubMed ] [ Google Scholar ]
- Spherical vs Angular Silica: Which Filler Performs Better and When?
- Ho et al. employed the Multiple-Path Particle Dosimetry (MPPD) model for aerosolization and determination of lung deposition of silver nanoparticles, which method may be broadened to other materials like mesoporous silica nanoparticles [ 87 ]. It suggests particle size (mean 18 nm), density, and generation approach as principal elements that determine aerosolization efficiency and inhaled dose. Simulations of airflow, diffusion, sedimentation, and impact through airway generations yield comparable alveolar deposition fractions for particles less than 100 nm in humans and rats. With the addition of species-specific parameters, such as respiratory rate, lung surface region, tidal volume, and finished with possible lobar- and airway-level analysis, the MPPD model makes realistic regional retention predictions. Given that mesoporous silica nanoparticles are of similar size and physicochemical properties, the same methodology can estimate their aerosolization and lung deposition. In summary, the MPPD model is a handy tool in the assessment of inhalation danger and in guiding the formulation of safer nanomaterials [ 87 ]. In another study, Ali et al. applied the MPPD model to simulate aerosolization and lung deposition of mesoporous silica nanoparticles [ 88 ]. Pre-characterized MSNs with pre-specified aerodynamic diameters were initially assessed through scanning mobility particle sizing to yield accurate size-distribution inputs. Asymmetric mouse airway geometry and physiological parameters such as respiratory rate, lung volume, and airflow were used in simulations that were approximated to provide a total lung deposition of about 45%, of which 37% was in the head, 27% in the tracheobronchial, and 36% in the pulmonary (alveolar) region. These predictions are in reasonable agreement with earlier in vivo findings, validating the model. MPPD analysis also indicated that smaller MSNs exhibit more alveolar deposition, with the larger particles being better in the upper airways. Through linking aerosolization efficiency (via size distribution and concentration) and regional deposition, this modeling approach orients optimization of nanoparticle size and generation techniques toward maximizing targeted lung delivery [ 88 ]. To achieve easier production of aerosols, the surface of nanoparticles is often provided with a polymer coating, thereby stabilizing their distribution and increasing dispersibility [ 56 ]. By lowering the particle size, deeper lung areas can be reached [ 25 ]. Particles smaller than 1 µm are capable of accumulating in the alveoli, but the ideal size range to achieve maximum efficiency is in the 200-500 nm range [ 25 ]. Nevertheless, another review cited that particle size in the range of 50-200 nm is ideal for maximizing drug localization by inhalation [ 89 ]. It has also been recommended that the perfect diameter is approximately 500 nm for phagocytosis by alveolar macrophages [ 89 ]. Li et al. nebulized PEI-PEG-coated MSNs (50 nm particle size) by standard nebulizers without compromising their structure, while keeping particles in their individual form within the water droplets [ 90 ]. The aerosol supplies convenient delivery of MSNs to all areas of the respiratory tract - nasal, tracheobronchial, and pulmonary - and they persist for a week following inhalation, mostly within alveolar macrophages. It offers intracellular targeted delivery of lung diseases without passing through the gastrointestinal and first-pass metabolism. In spite of decreased deep lung deposition in mice under nasal breathing, exposure is comparable to that of humans with inhalation. Toxicity tests revealed no tissue damage or inflammation, further supporting MSN inhalation as a safe and effective method for vast treatment of pulmonary diseases, feasible for clinical translation [ 90 ]. A study investigated the effect of surface chemistry on drug loading capacity, release kinetics, and antibiotic activity in pulmonary infections on S. aureus bacterial cultures [ 18 ]. The model drugs were isoniazid, rifampicin, and vancomycin. Remarkable absorption ability was observed only with thiol (-SH) grafted carriers for all the tested drugs [ 18 ]. The in vitro drug release study showed sustained, but limited release: the cumulative release of rifampicin was 78.5% after 12 days, estimated by antibiogram [ 18 ]. Interestingly, the MIC values of the MSN-drug complex were higher for the free drug, probably due to the delayed and incomplete release from the pores [ 18 ]. Wang et al. developed a polydopamine-coated MSN formulation co-loaded with Ziyuglycoside I and Oseltamivir for the treatment of viral pneumonia. Interestingly, in vitro and in vivo studies have demonstrated that this carrier provided immediate release of Oseltamivir (allows quick virus killing) but prolonged release of Ziyuglycoside I (cuts down the inflammatory response for a longer period) [ 62 ].
- Silica for Adhesives: Thickening, Thixotropy and Reinforcement Explained
Silica Manufacturer in China: How to Evaluate Quality, Capacity and Export Experience
What is silica (SiO₂)?
U.S. Silica Lyophilization can be safely used for heat-sensitive drug substances because the drug is formulated at low temperatures and low pressure. Another advantage compared to direct compression is that the poor flowability does not cause problems here, and the pore structure of the nanoparticle is not damaged in the absence of compression. The freeze-drying process can be divided into three main steps: freezing, primary drying, and secondary drying [ 101 ]. The loaded carriers are homogenized with the prepared polymer solution [ 102, 103 ], containing matrix agents (PEG, polyvinyl alcohol (PVA), hydroxyethyl cellulose (HEC), polyvinylpyrrolidone (PVP), alginate, dextran), cryoprotectants (sucrose, or sugar alcohols such as mannitol, sorbitol), surfactants (polysorbates, sorbitan monooleate), super disintegrants (croscarmellose sodium) [ 102 ]. The resulting dispersion is filled into blisters and then lyophilized [ 102, 103 ]. During the process, the desired tablet shape is formed, adapting to the shape of the blister [ 102 ]. They are characterized by rapid disintegration (less than 30 s), low moisture content, and rapid dissolution [ 41, 102, 103 ]. Elmowafy et al. effectively optimized lyophilized tablet formulations using quercetin-loaded MSN carriers [ 41 ]. PVP-K30 was used as a polymeric stabilizer, PEG 6000 as a co-binding polymer, and sucrose as a cryoprotectant. This freeze-dried formulation permits fast disintegration and low friability (less than 1%). Importantly, the saturation solubility and the dissolution rate, and so the oral bioavailability of the poorly water-soluble quercetin boosted particularly, and it can be further improved by sublingual application [ 41 ]. Utilizing the right composition, an orally dispersible tablet can be produced, which is why its sublingual use is advantageous, because the API goes directly into the systemic circulation (bypassing the enteral circulation, so the first pass impact does not apply), hence improving oral bioavailability [ 41, 100 ]. Besides immediate drug release, sustained and even targeted drug release is also available, provided by appropriate formulation, thus increasing the therapeutic possibilities. These days, gastroretentive and mucoadhesive freeze-dried tablets are also available, further broadening the spectrum [ 102, 103 ].
What is the difference between fumed silica and precipitated silica?
silica thickening agent
What drives silica raw material prices?
silica carrier
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.